NCT03176264 - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2017

Primary Completion Date

January 30, 2018

Study Completion Date

January 30, 2018

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

PDR001

400 mg every 4 weeks

DRUG

bevacizumab

5 mg/kg every 2 weeks

DRUG

mFOLFOX6

Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)

Trial Locations (1)

Novartis Investigative Site, Sutton